Search

Displaying results 1071 - 1080 of 5758 in total
  1. Drug

    Mestranol

    go.drugbank.com/drugs/DB01357
    ApprovedWithdrawn

    The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives.

    Mixtures: Norinyl 1/50 -(21-day Regimen), Norinyl 1/50 -(28-day Regimen)Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  2. Drug

    Docusate

    go.drugbank.com/drugs/DB11089
    ApprovedInvestigational

    However the effectiveness of docusate in treating constipation remains unclear, as several studies report docusate to be no more effective than placebo for increasing the frequency of stool or stool softening

    Mixtures: UltimateCare ONE NF, Prenatal Vitamin No 53 Iron Fum Folic Acid Docusate CA DHAProducts: Ag-docusate Sodium
  3. Drug

    Halothane

    go.drugbank.com/drugs/DB01159
    ApprovedVet approvedWithdrawn

    A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates
  4. Drug

    Norgestimate

    go.drugbank.com/drugs/DB00957
    ApprovedInvestigational

    Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with eth...

    Mixtures: Tri-previfem (21 Day), Tri-previfem (21 Day)Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  5. Drug

    PX-102

    go.drugbank.com/drugs/DB15416
    Investigational

    PX-102 is under investigation in clinical trial NCT01998672 (Multiple Ascending Oral Dose Phase I Study With Px-102).

  6. Drug

    PF-05105679

    go.drugbank.com/drugs/DB15450
    Investigational

    PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679).

  7. Drug

    PF-06305591

    go.drugbank.com/drugs/DB12106
    Investigational

    Pf 06305591 is under investigation in clinical trial NCT01776619 (Safety and Tolerability Study of Multiple Doses of PF-06305591).

  8. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular … [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease.

  9. Drug

    Enoximone

    go.drugbank.com/drugs/DB04880
    ApprovedInvestigationalWithdrawn

    Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure. Trials were halted...

  10. Drug

    IDM-2

    go.drugbank.com/drugs/DB05293
    Experimental

    IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.